OKYO PHARMA LTD (OKYO)

GG00BMFG5F62 - Common Stock

1.88  -0.04 (-2.08%)

After market: 1.82 -0.06 (-3.19%)

OKYO PHARMA LTD

NASDAQ:OKYO (9/26/2023, 7:24:41 PM)

After market: 1.82 -0.06 (-3.19%)

1.88

-0.04 (-2.08%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-14 2023-08-14
Earnings (Next)12-28 2023-12-28
Ins OwnersN/A
Inst Owners0.05%
Market Cap40.93M
Shares21.77M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts82.86
IPO07-17 2018-07-17
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

OKYO Daily chart

Company Profile

OKYO Pharma Ltd operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on developing an approach to dry eye care and ocular pain that is developing a lipidated chemerin-peptide drug candidate, OK-101, designed to target an ocular receptor controlling inflammation and ocular pain. The Company’s principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The firm operates through the research and development of biotechnological and pharmaceutical products segment. The Company’s technologies include Chemerin Receptor, OK-101 Drug Candidate and Preclinical Data. Its membrane anchored peptide (MAP) technology enabled the development of OK-101. Its drug candidate, OK-101, consists of a 10-mer C-terminal chemerin peptide sequence, a linker component, and an anchoring lipid domain. The Company’s wholly owned subsidiary is OKYO Pharma US Inc.

Company Info

OKYO PHARMA LTD

55 Park Lane

London

P: 442074952379.0

Employees: 7

Website: https://okyopharma.com/

OKYO News

News Image12 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!

News Image12 days ago - OKYO Pharma LTDOKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
News Image12 days ago - OKYO Pharma LTDOKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares

LONDON and NEW YORK, Sept. 15, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused...

News Image13 days ago - Seeking AlphaOKYO Pharma down 4%, withdraws public offering (NASDAQ:OKYO)

An ophthalmology-focused bio-pharmaceutical company OKYO Pharma (NASDAQ:OKYO) withdraws its proposed public offering of ordinary shares and its termination of Freedom Capital Markets as...

News Image13 days ago - OKYO Pharma LTDOKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
News Image13 days ago - OKYO Pharma LTDOKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares

LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO) (“OKYO” or the “Company”), an ophthalmology-focused...

OKYO Twits

Here you can normally see the latest stock twits on OKYO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example